BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) is a clinical-stage biopharmaceutical company focused on oncology that entered the public markets through a SPAC business combination. On August 12, 2026, the company filed a Form 424B3 prospectus supplement with the Securities and Exchange Commission under accession number 0001193125-26-345123, a filing type commonly used post-combination to register shares held by selling stockholders for resale. The company operates in the oncology and life sciences sector, developing targeted cancer therapies. Investors and analysts tracking BBOT's capital structure, filing history, and deal timeline can access the full dataset, including sponsor details and combination chronology, by signing up for a SpacDesk account at spacdesk.com.